Differences in surrogate threshold effect estimates between original and simplified correlation-based validation approaches

被引:5
作者
Schuermann, Christoph [1 ]
Sieben, Wiebke [1 ]
机构
[1] John Wiley & Sons Ltd, Atrium, Southern Gate, Chichester PO19 8SQ, W Sussex, England
关键词
surrogate endpoint validation; surrogate threshold effect; meta-analysis; RANDOMIZED CLINICAL-TRIALS; ADVANCED COLORECTAL-CANCER; END-POINTS; FREE SURVIVAL; METAANALYSIS; MODELS;
D O I
10.1002/sim.6778
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Surrogate endpoint validation has been well established by the meta-analytical correlation-based approach as outlined in the seminal work of Buyse et al. (Biostatistics, 2000). Surrogacy can be assumed if strong associations on individual and study levels can be demonstrated. Alternatively, if an effect on a true endpoint is to be predicted from a surrogate endpoint in a new study, the surrogate threshold effect (STE, Burzykowski and Buyse, Pharmaceutical Statistics, 2006) can be used. In practice, as individual patient data (IPD) are hard to obtain, some authors use only aggregate data and perform simplified regression analyses. We are interested in to what extent such simplified analyses are biased compared with the ones from a full model with IPD. To this end, we conduct a simulation study with IPD and compute STEs from full and simplified analyses for varying data situations in terms of number of studies, correlations, variances and so on. In the scenarios considered, we show that, for normally distributed patient data, STEs derived from ordinary (weighted) linear regression generally underestimate STEs derived from the original model, whereas meta-regression often results in overestimation. Therefore, if individual data cannot be obtained, STEs from meta-regression may be used as conservative alternatives, but ordinary (weighted) linear regression should not be used for surrogate endpoint validation. Copyright (C) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:1049 / 1062
页数:14
相关论文
共 13 条
  • [1] The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer
    Burzykowski, T
    Molenberghs, G
    Buyse, M
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2004, 167 : 103 - 124
  • [2] Validation of surrogate end points in multiple randomized clinical trials with failure time end points
    Burzykowski, T
    Molenberghs, G
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2001, 50 : 405 - 422
  • [3] Burzykowski T, 2005, THE EVALUATION OF SU
  • [4] Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation
    Burzykowski, Tomasz
    Buyse, Marc
    [J]. PHARMACEUTICAL STATISTICS, 2006, 5 (03) : 173 - 186
  • [5] Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49
  • [6] Progression-free survival is a surrogate for survival in advanced colorectal cancer
    Buyse, Marc
    Burzykowski, Tomasz
    Carroll, Kevin
    Michiels, Stefan
    Sargent, Daniel J.
    Miller, Langdon L.
    Elfring, Gary L.
    Pignon, Jean-Pierre
    Piedbois, Pascal
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5218 - 5224
  • [7] Korn EL, 2005, STAT MED, V24, P163, DOI 10.1002/sim.1779
  • [8] Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis
    Oba, Koji
    Paoletti, Xavier
    Alberts, Steven
    Bang, Yung-Jue
    Benedetti, Jacqueline
    Bleiberg, Harry
    Catalano, Paul
    Lordick, Florian
    Michiels, Stefan
    Morita, Satoshi
    Ohashi, Yasuo
    Pignon, Jean-pierre
    Rougier, Philippe
    Sasako, Mitsuru
    Sakamoto, Junichi
    Sargent, Daniel
    Shitara, Kohei
    Cutsem, Eric Van
    Buyse, Marc
    Burzykowski, Tomasz
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21): : 1600 - 1607
  • [9] SURROGATE ENDPOINTS IN CLINICAL-TRIALS - DEFINITION AND OPERATIONAL CRITERIA
    PRENTICE, RL
    [J]. STATISTICS IN MEDICINE, 1989, 8 (04) : 431 - 440
  • [10] Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials
    Shi, Qian
    Renfro, Lindsay A.
    Bot, Brian M.
    Burzykowski, Tomasz
    Buyse, Marc
    Sargent, Daniel J.
    [J]. COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2011, 55 (09) : 2748 - 2757